The Catalyst

Most Recent Posts

07.20.11

You should check-out the piece by Ken Thorpe that recently ran in U.S. News & World Report's Health section. The piece is entitled: Health Reform That Passes the Buck Is Short-Sighted.

07.19.11 | By Kate Connors

What disease can trace its roots back to the dinosaurs?

It's currently diagnosed in one out of five American adults...

...but it also affects 300,000 children, as well.

07.19.11
I've been looking over the new report from the McKinsey Global Institute featured at today's Atlantic's CEO summit on "The New Work Era." The report is entitled "An Economy that Works: Job Creation and America's Future" and it looks at job creation and what kind of things we need to be doing both in the near and long-term
07.18.11 | By Kate Connors
As we discuss the importance of jobs in the biopharmaceutical sector, and the dangers of policies that would ultimately lead to loss of these jobs, it's worth taking a moment to look at what these jobs really mean. As the Battelle report showed us, jobs within the sector support many other jobs outside the sector, many of which may not be what you'd expect, like day care centers and truck drivers.
07.15.11

David Brooks has a typically thoughtful column in today's New York Times. Brooks takes a look at the roll of healthcare costs in our budget debate and opines:

07.15.11 | By Kate Connors

New research, released today by the IMS Institute for Healthcare Informatics, affirms what we've been saying for awhile now: The average costs for medicines frequently used by Medicare Part D beneficiaries have declined significantly since the implementation of the program.

07.14.11 | By Kate Connors

Recently Bob Cobuzzi, Vice President of Corporate Development for Endo Pharmaceuticals, sat down in front of a camera for a few minutes to discuss the challenges faced by emerging American biopharmaceutical companies that are trying to reach markets outside the U.S.

07.14.11 | By Kate Connors

When discussing progress associated with medical innovation, we like to mention both life-saving and life-enhancing medicines. Why? Because so many debilitating chronic conditions may not be life-threatening, but the patients who live with them still deserve the best that healthcare has to offer.

07.13.11

With the new Battelle report focusing on how biopharmaceutical innovation helps to fuel the economy, I wanted to share a local view from Iowa. Tom Swegle is the Vice Chairman of the Iowa Biotechnology Association and he recently published a great oped in the Des Moines Register.

07.13.11 | By Kate Connors

Monday, we discussed how policies that undercut the biopharmaceutical research sector could lead to huge job losses, with an annual reduction in sector revenue of $20 billion potentially leading to as many as 260,000 lost jobs.

07.12.11 | By Kate Connors

An article in today's Washington Post discusses how generic drugs can benefit America's overall healthcare system. In fact, nearly 80 percent of all prescriptions written in the U.S. are for generics, according to IMS Health.

07.11.11 | By Kate Connors

It's no secret that the biopharmaceutical sector provides jobs - and a wide range of jobs, at that. We're not just researchers in lab coats. In terms of jobs we support, we're also the drivers of trucks that help medicines reach pharmacies, the construction workers and technicians who help construct the facilities and equipment necessary for manufacture of medicines, and more. Ultimately, it's an intricate web of workers that all play a role in the important work that we do.

07.08.11

A recent editorial in the New York Times delved into some overarching issues around coverage of cancer medicine. While the paper raises some interesting questions, it unfortunately missed a few key considerations in trying to come up with answers.

07.08.11

At PhRMA and our member companies, we're proud and excited by how the nearly 900 medicines now being developed to fight cancer may help patients struggling with the disease.

07.07.11 | By Kate Connors

This week, I had the chance to speak with Dr. Marc S. Ernstoff from Dartmouth College's Dartmouth-Hitchcock Medical Center. Dr. Ernstoff, a leading oncologist and melanoma researcher, took the time to explain to me some of the latest advances in the field.

Tell us how you became involved in melanoma research?

Pages